Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

1.4K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
Drug Clearance: Overview01:06

Drug Clearance: Overview

603
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
603
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

1.8K
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.8K
Drug Absorption: Overview01:17

Drug Absorption: Overview

2.9K
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of COVID-19 on sexual behavior, male sexual function, and reproductive health: an interdisciplinary narrative review from a urological perspective.

International urology and nephrology·2026
Same author

HoLEP in patients with and without catheter-dependent acute urinary retention: Surgical and functional outcomes.

Actas urologicas espanolas·2026
Same author

Comparison of postvoid residual urine volumes among lower urinary tract parameters in pediatric and adolescent age groups: A cohort study at a tertiary referral center.

Actas urologicas espanolas·2025
Same author

Semen quality and metabolic profile in people with type 1 diabetes with and without erectile dysfunction: a cross-sectional study.

Journal of endocrinological investigation·2024
Same author

Intestinal microbiota, intestinal permeability and the urogenital tract: is there a pathophysiological link?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

The role of multiparametric resonance and biopsy in prostate cancer detection: comparison with definitive histological report after laparoscopic/robotic radical prostatectomy.

Abdominal radiology (New York)·2020
Same journal

Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.

European review for medical and pharmacological sciences·2026
Same journal

Intracoronary stem cell transplant in ischemic heart disease: a meta-analysis of randomized trials.

European review for medical and pharmacological sciences·2026
Same journal

From models to medicine: advanced preclinical systems and AI enabling RNA therapeutics in triple-negative breast cancer.

European review for medical and pharmacological sciences·2026
Same journal

Association of serum asprosin levels with obesity indices and metabolic parameters in adults.

European review for medical and pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K

Flavoxate: present and future.

D Arcaniolo1, S Conquy, T Tarcan

  • 1Department of Urology, University "Federico II", Naples, Italy. davide_arcaniolo@yahoo.it.

European Review for Medical and Pharmacological Sciences
|March 26, 2015
PubMed
Summary
This summary is machine-generated.

Flavoxate effectively treats overactive bladder (OAB) symptoms, improving bladder capacity and reducing urinary urgency and incontinence. It offers a favorable safety profile compared to other OAB medications.

More Related Videos

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

8.8K
Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K
Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

8.8K
Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.7K

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Overactive bladder (OAB) is a common condition characterized by urinary urgency, frequency, and incontinence.
  • Current treatments for OAB aim to alleviate these symptoms and improve quality of life.

Purpose of the Study:

  • To review the available evidence on the efficacy and safety of flavoxate for treating overactive bladder (OAB).

Main Methods:

  • A non-systematic review of studies was conducted.
  • Medline database was searched for relevant literature without time limitations.

Main Results:

  • Flavoxate, an antispasmodic, inhibits phosphodiesterases, has moderate calcium antagonistic activity, and a local anesthetic effect.
  • Preclinical and clinical studies demonstrate flavoxate significantly increases bladder volume capacity (BVC) compared to emepronium bromide and propantheline.
  • Clinical trials show flavoxate improves OAB symptoms like frequency, urgency, incontinence, and pain, with a better safety profile than competitors.

Conclusions:

  • Extensive research and clinical practice confirm flavoxate's efficacy and tolerability for OAB treatment.
  • Further studies are needed to solidify flavoxate's role in OAB management and explore its use in other conditions, such as lower urinary tract infections.